DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
09 Novembro 2023 - 10:25AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic
stroke, today announced that Rick Pauls, its President and CEO and
Dave Wambeke, its Chief Business Officer will be participating in
the 14th Annual Craig-Hallum Alpha Select Conference being held in
New York on Thursday, November 16, 2023.
Investors and attendees that would like to schedule a meeting
with DiaMedica’s management can contact their Craig-Hallum
representative to arrange a meeting.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active and clinically studied recombinant
(synthetic) form of the KLK1 protein, an established therapeutic
modality in Asia for the treatment of acute ischemic stroke and
other vascular diseases. For more information visit our website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109154887/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
